Clinical Trial Update: Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating gemcitabine and Abraxane plus placebo vs with demcizumab in first-line metastatic pancreatic ductal adenocarcinoma; study completed wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)
• Demcizumab (demcizumab)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: OncoMed Pharmaceuticals, Inc. | Conditions: Pancreatic Cancer | Phase 2 | Status: COMPLETED | Results posted: 2018-08-08